Association between CT-Quantified Body Composition and Recurrence, Survival in Nonmetastasis Colorectal Cancer Patients Underwent Regular Chemotherapy after Surgery

Table 1

Baseline patient characteristics.

	All	Xelox ()	Folfox/Folfiri ()	value
Characteristics	Patient (%)
Age (range)				0.297
Median (range)
<50	45 (20.3%)	34 (19.0%)	11 (26.2%)
≥50	176 (79.7%)	145 (81.0%)	31 (73.8%)
Gender				0.161
Male	129 (53.1%)	103 (57.5%)	26 (63.4%)
Female	92 (46.9%)	66 (42.5%)	15 (36.6%)
T stage				0.173
T2-3	116 (19.5%)	93 (52.0%)	23 (54.8%)
T4	105 (80.5%)	76 (48.0%)	19 (45.2%)
Lymph node metastasis				0.135
No	138 (56.3%)	116 (64.8%)	22 (52.4%)
Yes	86 (43.7%)	63 (35.2%)	20 (47.6%)
TNM stage				0.197
I-II	130 (54.5%)	109 (60.9)	21 (50.0)
III	91 (45.5%)	70 (39.1)	21 (50.0)
BMI				<0.001
<18.5	12 (5.4%)	8 (4.5%)	4 (9.5%)
18.5-25	168 (76.0%)	135 (75.4%)	33 (78.6%)
≥25	41 (18.6%)	36 (20.1%)	5 (11.9%)
MetS				0.893
No	196 (88.7%)	159 (88.8%)	37 (88.1%)
Yes	25 (11.3%)	20 (11.2%)	5 (11.9%)
ECOG				<0.001
1	77 (34.8%)	71 (39.7%)	6 (14.3%)
2	119 (53.8%)	99 (55.3%)	20 (47.6%)
>3	25 (11.3%)	9 (5.0%)	16 (38.1%)
Status
Alive	156 (79.1%)	133 (74.3)	23 (54.8%)
Death	65 (20.9%)	46 (25.7)	19 (45.2%)